Fox Run Management, L.L.C. Glaukos Corp Transaction History

Fox Run Management, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$59.53 - $85.11 $315,985 - $451,763	5,308 New	5,308 $421,000
Q4 2022 Feb 07, 2023	BUY	$40.82 - $57.75 $16,042 - $22,695	393 Added 5.86%	7,100 $310,000
Q3 2022 Nov 07, 2022	BUY	$46.84 - $58.49 $314,155 - $392,292	6,707 New	6,707 $357,000
Q1 2022 May 10, 2022	SELL	$44.33 - $57.82 $305,832 - $398,900	-6,899 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$40.27 - $56.99 $277,822 - $393,174	6,899 New	6,899 $307,000
Q2 2021 Aug 05, 2021	SELL	$73.06 - $97.7 $240,002 - $320,944	-3,285 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$70.43 - $97.42 $231,362 - $320,024	3,285 New	3,285 $276,000

342

46.8M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.45B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.